Literature DB >> 22236673

Radiosurgery for brain metastases.

Douglas Kondziolka1, John C Flickinger, L Dade Lunsford.   

Abstract

We discuss the current literature on the role of stereotactic radiosurgery in the multidisciplinary management of brain metastases and focus on the level of evidence that addresses key management questions. We reviewed the literature on the different roles of radiosurgery, radiotherapy, and resection, and in particular the 2009 Guidelines project of the Joint Section on Tumors of the AANS/CNS. Retrospective case series, matched cohort studies, and randomized trials show specific survival and local tumor control benefits after radiosurgery. Radiosurgery is an effective and safe minimally invasive option for patients with brain metastases. Randomized trials include tumors of different histologies which can detract from their relevance to specific tumor types.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 22236673     DOI: 10.1159/000331184

Source DB:  PubMed          Journal:  Prog Neurol Surg        ISSN: 0079-6492


  4 in total

1.  Local control of melanoma brain metastases treated with stereotactic radiosurgery.

Authors:  Hilary P Bagshaw; David Ly; Gita Suneja; Randy L Jensen; Dennis C Shrieve
Journal:  J Radiosurg SBRT       Date:  2016

2.  Stereotactic radiosurgery for the treatment of melanoma and renal cell carcinoma brain metastases.

Authors:  Shelly Lwu; Pablo Goetz; Eric Monsalves; Mandana Aryaee; Julius Ebinu; Norm Laperriere; Cynthia Menard; Caroline Chung; Barbara-Ann Millar; Abhaya V Kulkarni; Mark Bernstein; Gelareh Zadeh
Journal:  Oncol Rep       Date:  2012-11-14       Impact factor: 3.906

3.  The biological effect of large single doses: a possible role for non-targeted effects in cell inactivation.

Authors:  Marlon R Veldwijk; Bo Zhang; Frederik Wenz; Carsten Herskind
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

Review 4.  Radioresistance of Brain Tumors.

Authors:  Kevin Kelley; Jonathan Knisely; Marc Symons; Rosamaria Ruggieri
Journal:  Cancers (Basel)       Date:  2016-03-30       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.